expression in differentiating NSC provide further insights on designing possible drug therapies for autism. Even though the exposure of RTT cell lines (fibroblasts) to lower doses of decitabine for a longer period did not activate MECP2 expression [65], our results indicate that moderate dose of decitabine can induce Mecp2/MeCP2 expression within a shorter period. However, inhibition of MeCP2 by withdrawal of decitabine as well as other observed changes in DNA methyl marks implies that such drug therapy should be administrated with great caution.
